Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 107,652,328
  • Shares Outstanding, K 1,632,580
  • Annual Sales, $ 20,776 M
  • Annual Income, $ 1,007 M
  • 36-Month Beta 1.09
  • Price/Sales 5.23
  • Price/Cash Flow 18.91
  • Price/Book 9.19

Price Performance

See More
Period Period Low Period High Performance
1-Month
58.44 +16.00%
on 02/06/18
70.05 -3.23%
on 02/16/18
+4.36 (+6.87%)
since 01/23/18
3-Month
58.44 +16.00%
on 02/06/18
70.05 -3.23%
on 02/16/18
+6.65 (+10.88%)
since 11/22/17
52-Week
51.56 +31.48%
on 06/07/17
70.05 -3.23%
on 02/16/18
+12.02 (+21.55%)
since 02/23/17

Most Recent Stories

More News
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Bristol-Myers Squibb Company (NYSE:BMY) from...

BMY : 67.84 (+2.88%)
Pharma Stock Roundup: AZN's Imfinzi Gets 2nd FDA Nod, MRK to Buy Australian Firm

Key announcements this week included the FDA approval for a second indication of AstraZeneca's (AZN) Imfinzi and an acquisition offer by Merck (MRK).

AZN : 33.99 (+0.89%)
NVO : 53.74 (+1.28%)
VYGR : 28.30 (+9.44%)
MRK : 54.90 (+0.60%)
IONS : 50.73 (+1.70%)
ABBV : 118.42 (+0.73%)
ACOR : 25.95 (-1.70%)
BMY : 67.84 (+2.88%)
The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Bristol-Myers Squibb Company (BMY)

The Klein Law Firm announces the commencement of an investigation of Bristol-Myers Squibb Company (NYSE: BMY) concerning possible violations of federal securities laws.

BMY : 67.84 (+2.88%)
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Bristol-Myers Squibb Company to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern...

BMY : 67.84 (+2.88%)
Pomerantz Law Firm Announces the Filing of a Class Action against Bristol-Myers Squibb Company and Certain Officers - BMY

Pomerantz LLP announces that a class action lawsuit has been filed against Bristol-Myers Squibb Company ("Bristol-Myers" or the "Company") (NYSE:BMY) and certain of its officers. The class action, filed...

BMY : 67.84 (+2.88%)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Bristol-Myers Squibb Company (BMY) & Lead Plaintiff Deadline: April 10, 2018

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Bristol-Myers Squibb Company ("Bristol-Myers" or the "Company") (NYSE:BMY)...

BMY : 67.84 (+2.88%)
Will Cabometyx Fuel Exelixis' (EXEL) Earnings in Q4 Again?

Exelixis (EXEL) is likely to beat on earnings in the fourth quarter (results due on Feb 26) driven by growth in Cabometyx sales.

GEMP : 6.60 (-2.87%)
EXEL : 29.29 (+0.65%)
RHHBY : 29.7400 (-0.37%)
BMY : 67.84 (+2.88%)
Market Trends Toward New Normal in Container Store, Signature Bank, Bridgepoint Education, Skechers U.S.A., Bristol-Myers Squibb, and Mastercard -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Container Store (NYSE:TCS),...

SKX : 39.67 (+3.82%)
MA : 175.00 (+1.19%)
TCS : 4.82 (+1.47%)
BPI : 6.43 (+0.16%)
SBNY : 151.42 (+1.42%)
BMY : 67.84 (+2.88%)
Liquidity Services Announces Upcoming Sales for Biopharmaceutical Assets on its Global Marketplace, GoIndustry DoveBid

Liquidity Services (NASDAQ:LQDT), a global solution provider in the reverse supply chain with the world's largest marketplace for business surplus, is pleased to highlight its upcoming sales of biopharmaceutical...

LQDT : 7.28 (+0.34%)
BMY : 67.84 (+2.88%)
AstraZeneca's (AZN) Imfinzi Gets FDA Nod for Label Expansion

Data shows that AstraZeneca's (AZN) Imfinzi improved PFS by more than 11 months in comparison to placebo in the concerned patient population.

AZN : 33.99 (+0.89%)
MRK : 54.90 (+0.60%)
NVS : 85.25 (+0.06%)
BMY : 67.84 (+2.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious...

See More

Key Turning Points

2nd Resistance Point 67.41
1st Resistance Point 66.67
Last Price 67.80
1st Support Level 65.53
2nd Support Level 65.13

See More

52-Week High 70.05
Last Price 67.80
Fibonacci 61.8% 62.99
Fibonacci 50% 60.81
Fibonacci 38.2% 58.62
52-Week Low 51.56

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.